Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature.
OBJECTIVE
Epithelial ovarian cancer is the leading cause of death from gynecologic malignancies amongst American women. Emerging proteomic technologies have promise for early diagnosis and in advancing treatment directions. Application of these technologies has produced new biomarkers, diagnostic approaches, and understanding of disease biology.


RESULTS
Mass spectral blood and tissue analysis has yielded new putative biomarkers that require further validation and assessment of diagnostic specificity and sensitivity. Protein signature patterns derived from mass spectrometry datastreams have been modeled and are moving into validation. Tissue-based protein analysis has led to identification of tumor and stromal protein and signal activation events in ovarian cancer. Clinical trials are now ascertaining tissue samples prior to and during therapy with molecularly targeted agents to evaluate modulation of targeted signaling pathways. Finally, proteomic analysis of tissues and metastases will outline biochemical events underlying the metastatic phenotype of ovarian cancer.


CONCLUSIONS
Proteomic approaches are experimental technologies applied to ovarian and other cancers. Proper validation and use of findings may advance our understanding of biochemical events that have complicated successful detection and intervention. This knowledge is the first step in fulfilling the promise of personalized molecular medicine.
Laboratory of Pathology, National Cancer Institute and NCI/FDA Clinical Proteomics Program Bethesda, Maryland, USA.
Edwin M
EM
Posadas
Ben
B
Davidson
Elise C
EC
Kohn
D014408:Biomarkers, Tumor; D005260:Female; D006801:Humans; D009375:Neoplasms, Glandular and Epithelial / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy*; D040901:Proteomics / Q000379:methods*; D015398:Signal Transduction
D014408:Biomarkers, Tumor